With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …

Immunoconjugates—monoclonal antibodies (mAbs) coupled to highly toxic agents,
including radioisotopes and toxic drugs (ineffective when administered systemically alone) …

Nanoparticles have recently emerged as a promising class of carriers for the co-delivery of
multiple drugs. Combination therapies of small-molecule drugs are common in clinical …

The detection of cell-bound proteins that are produced due to aberrant gene expression in
malignant tumors can provide important diagnostic information influencing patient …

Evolutionary pressure has selected antibodies as key immune molecules acting against
foreign pathogens. The development of monoclonal antibody technology has allowed their …

Noninvasive molecular imaging approaches include nuclear, optical, magnetic resonance
imaging, computed tomography, ultrasound, and photoacoustic imaging, which require …

Inorganic nanoparticles (NPs) including semiconductor quantum dots (QDs), iron oxide NPs
and gold NPs have been developed as contrast agents for diagnostics by molecular …

Over the last twenty-five years 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid
(DOTA) has made a significant impact on the field of diagnostic imaging. DOTA is not the …

The noninvasive detection and quantification of CD8+ T cells in vivo are important for both
the detection and staging of CD8+ lymphomas and for the monitoring of successful cancer …

Identification of cancer cell–surface biomarkers and advances in antibody engineering have
led to a sharp increase in the development of therapeutic antibodies. These same advances …